Intas Pharmaceuticals Ltd.
http://www.intaspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intas Pharmaceuticals Ltd.
Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
Keeping Track: US FDA Approves Amgen’s Lumakras, Myovant’s Myfembree; New Claims For Biohaven’s Nurtec, BMS’ Zeposia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.
Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.
Company Information
- Industry
- Services
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
- Vaccines
-
Drug Delivery
- Controlled Release
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Accord Healthcare Ltd.
- Essential Pharmaceuticals, LLC
- Intas Biopharmaceuticals